Conference Reactions
•
December 9, 2022
SABCS Reactions - MonarchE
Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes
Read more